VWF-Targeting Aptamers with Modified Nucleotides and PEGylation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antithrombotic drugs used to prevent and treat thrombosis face challenges with hemorrhagic risk due to lack of rapid and predictable reversibility, and existing VWF-targeting aptamers have limitations in stability, size, and circulation time.
Innovation Solution
Development of new VWF-targeting aptamers with increased stability against nuclease degradation, smaller size for easier chemical synthesis, and extended circulation times, along with antidotes for rapid reversal, to prevent and treat blood clots effectively.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing VWF-targeting aptamers are used, then anti-thrombotic activity is achieved, but stability against nuclease degradation is insufficient
Solution Approach 1:
The patent modifies the chemical structure of aptamers by incorporating modified nucleotides (such as 2'-fluoro, 2'-O-methyl, or L-O-4) to change the chemical parameters of the aptamer backbone. These modifications increase resistance to nuclease degradation while maintaining binding affinity to VWF, directly resolving the stability issue.
Solution Approach 2:
The patent creates composite aptamer structures by combining modified nucleotides with conventional nucleic acid backbones. This composite approach integrates the stability benefits of modified nucleotides with the functional properties of traditional aptamer structures, achieving both stability and functionality.
2Duration of action of moving object
If existing VWF-targeting aptamers are used, then anti-thrombotic activity is achieved, but circulation time is insufficient
Solution Approach 1:
The patent modifies aptamer parameters by adding PEGylation (polyethylene glycol conjugation) to change the physical-chemical properties of the aptamer. This modification increases the circulation time in vivo by reducing renal clearance and proteolytic degradation, directly addressing the insufficient circulation duration problem.
Solution Approach 2:
The patent uses PEG as an intermediary molecule that conjugates to the aptamer. This intermediary extends the circulation time by acting as a protective barrier against degradation and facilitating renal clearance, thereby increasing the duration of anti-thrombotic activity.
3Ease of manufacture
If existing VWF-targeting aptamers are used, then anti-thrombotic activity is achieved, but size is too large for efficient chemical synthesis
Solution Approach 1:
The patent segments the aptamer into smaller, more manageable nucleotide sequences that can be synthesized more efficiently. By reducing the overall length of the aptamer while maintaining the critical binding region, the patent improves chemical synthesis efficiency without compromising VWF binding affinity.
Solution Approach 2:
The patent extracts and removes unnecessary nucleotides from the aptamer sequence, retaining only the essential elements required for VWF binding. This extraction reduces the aptamer size and simplifies chemical synthesis while preserving the functional activity.
4Reliability
If antithrombotic drugs are used to prevent thrombosis, then thrombotic events are reduced, but hemorrhagic risk increases due to lack of rapid reversibility
Solution Approach 1:
The patent creates a dynamic system where the aptamer can be rapidly reversed by administering an antidote. This dynamic reversibility allows the therapeutic effect to be turned off quickly, reducing hemorrhagic risk while maintaining thrombosis prevention during the active phase.
Solution Approach 2:
The patent establishes a feedback mechanism through the development of specific antidotes that can detect and reverse aptamer binding. This feedback system enables rapid control over the therapeutic effect, allowing clinicians to switch from thrombosis prevention to hemorrhage prevention as needed.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new VWF-targeting aptamers demonstrate enhanced stability, smaller size, and longer circulation times, offering improved anti-thrombotic and thrombolytic activity with the ability to rapidly reverse their effects, thus addressing the limitations of existing therapies while minimizing hemorrhagic risks.
Implementation Method 1
Aptamers are single-stranded nucleic acids that adopt specific secondary and tertiary structures based on their sequence which enables specific binding to their target
Implementation Method 2
new VWF-targeting aptamers having increased stability against nuclease degradation
Data Source
AI summary
Provided herein are aptamers capable of inhibiting the activity of Von Willebrand Factor (VWF). Pharmaceutical compositions comprising these aptamers are also provided. Methods of preventing blood clot formation in a subject by administering the aptamers are provided and methods of treating a blood clot by administering a VWF-targeting agent are also provided.